New

Injectsense

The AI engine Fit Assessment

Beta

Injectsense develops digital health solutions that operate within the pharmaceutical industry, leveraging field-level sensor technologies for continuous patient monitoring.

Blurb

Monitoring therapy effectiveness (glaucoma) through miniaturized, autonomous in-vivo sensing and data uploading to cloud database.

HQ Location

Emeryville (United States)

Founded

2014

Employees

11 - 50

Total funding raised

$17.44M

Funding Status

Convertible Note, $2.50M, November 15, 2023
Subspaces
  • Remote Patient Monitoring

Injectsense: Improved Care Through Continuous Information



Injectsense enables tracking of progressive disease indicators and improved therapy management by providing continuous, clinically actionable information through an injectable ultra-miniature sensor coupled with a secure digital health platform. Our sensor, which can be delivered during a single doctor's office visit, transforms the care model by enabling medical teams to track the disease at the pace of its evolution, whether months or years, receive early warning signs and provide preventive therapy. The configurable-on-demand sensor monitors patients 24/7, requires no patient lifestyle changes and reduces the need for medical office visits. More significantly, it allows physicians to establish an individual patient baseline for comparison, to receive data quickly at any time of day, to see histories and hourly dynamic disease state before irreversible damage is done, and to increase the effectiveness of drug therapy by tracking the effects of pharmaceuticals on key indicators over time.